



Supplementary Figure 2: The JNK inhibitor SP600125 elicits different phenotypes depending on concentration and timing of treatment. Embryos were treated during different stages with different concentrations of SP600125 as indicated. **A,B**, Treatment between stage 9 and 13 ($30 \mu\text{M}$) results in gastrulation defects at stage 13. **C,D**, Treatment between stage 11 and 22 with a high concentration ($30 \mu\text{M}$) results in an open neural plate phenotype at stage 23. **E,F**, Treatment with a lower concentration ($12.5 \mu\text{M}$) between stage 11 and 22 results in small eyes (arrow head) at stage 35/36. Panels E and F are identical to Figure 2 F and H of the manuscript.